2023 was an exciting year at ImmunoScape, featuring transformative technical progress, new partnerships, expert additions to our leadership team and more. Read our...
The collaboration seeks to produce novel off-the-shelf TCR-based bispecific molecules designed to overcome current limitations in cell therapy approaches against solid...
MiNK Therapeutics combines its unique, proprietary library of T-cell antigens with ImmunoScape’s cutting-edge platform for rapid discovery of novel T-cell...
Therapeutics for solid tumors remain in a nascent corner of cancer research despite representing 90% of all cancers in adults. Thirty years after the first Chimeric...
ImmunoScape Appoints Systems Immunology and Computational Biology Expert Dr. John Tsang to its Scientific Advisory Board Expertise from award-winning computational...
ImmunoScape’s Andreas Wilm offers a behind the scenes look at the machine learning models we trained for research published in Cell Press’ Cell Reports – which...
ImmunoScape Uses Machine Learning to Accurately Predict Antigen Specificity Based on T-Cell Phenotypes in New Peer-Reviewed Research ImmunoScape’s platform accelerates...
Ayesha Siddiqui from BioSpectrum Asia spoke with our CEO and Co-Founder Choon-Peng (Choon) Ng about the progress around cancer research in Asia for her recent piece....
Our CEO and co-founder, Choon-Peng (Choon) Ng recently spoke with BioSpectrum Asia about how our unique Deep Immunomics and machine learning platforms can discover and...